News & Events about Immunovant Inc.
Immunovant, Inc. (NASDAQ:IMVT Get Rating) insider Julia G. Butchko sold 60,490 shares of the stock in a transaction that occurred on Wednesday, January 11th. The shares were sold at an average price of $16.79, for a total value of $1,015,627.10. Following the transaction, the insider now ...
Globe Newswire
2 months ago
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at ...
Globe Newswire
2 months ago
IMVT-1402, a next generation, subcutaneously administered, neonatal fragment crystallizable receptor (FcRn) inhibitor unveiledNew development programs for batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves disease announcedPhase 3 trials of batoclimab in myasthenia ...
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing PR Newswire PALM BEACH, Fl, Oct. 5, 2022 PALM BEACH, Fl, Oct. 5, 2022...
Globe Newswire
3 months ago
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an ...